Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease?

Developments in biological standardization

Volumn 89, Issue , 1997, Pages 379-389

  Granoff, D M ^a   Rappuoli, R ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE;

BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; DRUG APPROVAL; EPIDEMIOLOGY; HUMAN; IMMUNOLOGY; INFANT; LICENSING; PERTUSSIS; REVIEW;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CLINICAL TRIALS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; DRUG APPROVAL; HUMANS; INFANT; LICENSURE; SEROEPIDEMIOLOGIC STUDIES; WHOOPING COUGH;

EID: 0030623718     PISSN: 03015149     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)